
















































Cardiac resynchronization therapy in the real
world: need to focus on implant rates, patient
selection, co-morbidities, type of devices, and
complications
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This editorial refers to ‘Utilization and in-hospital compli-
cations of cardiac resynchronization therapy: trends in the
United States from 2003 to 2013’, by S.M. Hosseini et al.,
doi:10.1093/eurheartj/ehx100.
Heart failure (HF) affects 1–2% of the population in developed coun-
tries, with a higher prevalence in patients >70 years old. These figures
are likely to increase in the near future, as a result of the progressive
ageing of populations.1 It can be estimated that 15 of 900 million
Europeans and5.7 of 300 million US Americans will develop HF.1,2
Cardiac resynchronization therapy (CRT) was introduced >20
years ago as a compassionate treatment for selected patients with
drug-refractory HF, and its development was based on the pioneer-
ing experiences done in France3 Nowadays CRT is a cornerstone of
HF therapy, with a positive impact on both morbidity and mortality in
appropriately selected patients, according to the evidence provided
by several randomized controlled trials.1,3,4 Despite these premises,
CRT implementation in the ‘real world’ is variable, depending on sev-
eral factors, according to what has been shown by registries and
surveys.3,5
In this issue of the journal, Hosseini et al. report on the trends of
in-hospital CRT device implantations from 2003 to 2013 in the USA.6
No temporal trend was recorded in the overall estimated CRT im-
plantation rate or in the ratio between CRT pacemakers (CRTPs)
and CRT defibrillators (CRTDs). In the same period, the indications
for CRT widened, as reported in the consensus guidelines,4,7 but the
criteria to choose a CRTP or a CRTD device have always been a mat-
ter of debate.1,4 This was not clarified by the COMPANION
(Comparison of Medical Therapy, Pacing, and Defibrillation in Heart
Failure) trial, which indeed included a CRTD and a CRTP arm, as well
as a medical therapy arm, but it was powered to compare device
therapy with optimized medical therapy and not to compare the two
device treatments directly.7 However, the cost of CRTD devices is
approximately three-fold that of CRTPs and the battery duration is
significantly lower, with important financial implications. These con-
siderations can explain, at least partially, the heterogeneity in CRT
implants and particularly the proportion of CRTDs with respect to
all biventricular devices. As shown in Figure 1 (based on implant data
from 2013, or 2012 if data were unavailable),8–10 a huge heterogen-
eity in implantation rates for CRT devices exists across countries be-
longing to the European Society of Cardiology (ESC), ranging from 7
per million inhabitants in the Russian Federation to 221 per million in-
habitants in Germany. Notably, in the USA the reported rate of im-
plantations is >2-fold that of Germany. Several factors seem to
influence this variability: the financial status of healthcare systems, the
organization of care, demography, and cultural factors.11 It is note-
worthy that within Europe the reported variations also correspond
to a 20-fold variability in the number of CRT implanting centres.9
Several open issues remain in patient selection for CRT, as the
wide variability within the same country or even the same region
clearly highlights, for implantation of both CRT devices and implant-
able cardioverter-defibrillators.10,11
The ratio between CRTDs and CRTPs, as shown in Figure 1, is a
further source of variability between European countries and the
USA. The prevalence of CRTD implants as a proportion of all CRT
devices ranges between 11% in the Russian Federation and 88% in
Germany, in the latter being even higher than what was reported for
the USA.9,10
In the USA, the rate of CRTP implants nearly doubled from 2003
to 2013; this occurred in parallel with an increase in the mean age of
patients implanted with a CRTP and the increasing rate of implants in
older patients, often performed in the setting of an ‘ablate and pace’
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..strategy, which may explain this trend.10 A more precise assessment
of the outcomes of patients implanted with a CRTP is needed,
through prospective registries.
In consideration of the marked increased in device implants which
occurred in the last 20 years, a specific interest emerged in detecting
device complications, with the aim to predict and possibly minimize
their occurrence. It is noteworthy that most of these complications
are associated with increased patient morbidity, healthcare costs, and
possibly increased mortality.12–15 In this regard, Hosseini et al.
showed a significant increase in the frequency of in-hospital complica-
tions between 2003 and 2013.6 On average, 6.1% of the procedures
presented at least one complication (6.04% and 6.54% for CRTD and
CRTP implants, respectively) in the study period, with a significant
temporal trend (<0.01). This was associated with an increase in the
frailty of CRT candidates according to the temporal trend in the
Deyo–Charlson Co-morbidity Index (P = 0.002). In particular, older
age, female sex, non-elective admission, and Deyo–Charlson Co-
morbidity Index were independent predictors of in-hospital compli-
cations. The finding that non-elective admissions, which may be
related to clinical instability and urgent admission, are associated with
increased in-hospital complications integrates previous findings indi-
cating that this patient setting is a significant determinant of adverse
outcomes in the long term, in terms of mortality and hospitaliza-
tions.16 It is noteworthy that beyond complications, co-morbidities
are a major driver of outcomes. In a real-world long-term registry of
700 CRTD patients followed for 4 years, co-morbidities (ex-
pressed by the Charlson co-morbidity index), as well as age, male
gender, advanced NYHA class, and implant during unplanned, urgent
hospitalization were significant independent predictors of death/car-
diac transplant.16
Widening the perspective, co-morbidities are relevant for the
management and the outcomes of all the patients with HF, also inde-
pendently of CRT.1,17 Anaemia, chronic kidney disease, chronic ob-
structive pulmonary disease, and diabetes are co-morbidities
associated with advanced age and higher NYHA functional class, and
are strongly associated with adverse outcomes and hospitalizations,
that with a multidisciplinary management could be prevented or at
least appropriately managed in a substantial proportion of cases.17
According to this background, a patient’s age and the most important
co-morbidities, primarily advanced chronic kidney disease,17,18
should be carefully considered in the decision between a CRTP and
CRTD,4,5 and real-world registries should be used to monitor the
outcome according to specific patient characteristics, trying to im-
prove our knowledge.
Figure 1 Implantation rates of CRT devices per million inhabitants among countries within the European Society of Cardiology during 2013 (2012
in some nations, indicated by *, when data for 2013 are missing), according to the European Heart Rhythm Association (EHRA) White Book8,9 and
according to data sets related to Medicare enrollees in the USA.10 Only countries with >_250 CRT implants have been included. *2012 data;
**Medicare population; AT, Austria; BE, Belgium; BG, Bulgaria; CH, Switzerland; CZ, Czech Republic; DE, Germany; DK, Denmark; EG, Egypt; ES,
Spain; FI, Finland; FR, France; GR, Greece; HU, Hungary; IE, Ireland; IL, Israel; inhab. inhabitant; IT, Italy; NL, The Netherlands; NO, Norway; PL,






















































































.Hosseini et al.6 reported a rate of acute in-hospital periprocedural
complications, based on analysis of International Classification of
Disease 9th Revision, Clinical Modification (ICD-9-CM) codes, of
6.1% overall which is lower than what was previously reported. In
the report on data collected between 2010 and 2011 in the national
clinical database on pacemaker and defibrillator implants in Denmark,
Kirkfeldt et al.12 showed an overall 9.5% complication rate after im-
plant of pacemakers, defibrillators, or CRT devices. The risk of com-
plications was higher in the presence of some patient factors (female
gender, underweight), organizational issues (centres with an annual
volume of <750 procedures, emergency procedure, operator with
an annual volume of <50 procedures), or implanted system factors
(CRTD device, system upgrade, or lead revision). These differences
can easily be attributed to the method adopted for event assessment
(ICD-9-CM analysis vs. prospective adjudication); however, the time
window and the type of procedure are further elements to be care-
fully considered, especially for device infections. Several reports high-
lighted that complications are greatly increased in upgrade
procedures (vs. first implant), with figures that can exceed 15% within
90 days.12–15 This is particularly true for device-related infections,
which are the more feared complications since they are associated
with high risk of death and costs for healthcare systems.13–15
Moreover, this type of infection commonly manifests weeks and
months (even years) after discharge, especially in more frail patients,
and only a careful preventive management coupled with a strict fol-
low-up can help in controlling the spread of device infections.13,14
Only large registries with appropriate size and design can help in im-
proving our knowledge in this field, which is now one of the major
struggles for device therapy.
In summary, improved knowledge of the rate of implantations of
CRTP and CRTD devices in different geographical and organizational
settings, coupled with evaluation of potential under-referral is cur-
rently needed. Moreover, a better assessment of the short- and long-
term outcome of patients implanted with a CRT, of the impact of co-
morbidities in different settings of patients implanted with CRTP or
CRTD devices, as well as better prediction and minimization of
device-related complications will be crucial in order to improve pa-
tient selection according to clinical profile and to better define the
type of device to be implanted (CRTD or CRTP). In this perspective,
a proper evaluation of patients in the ‘real world’ may offer the
chance to verify the impact of new models of care for HF patients,
also with the contribution of innovative technologies, such as telemo-
nitoring. Data from large data sets will be of great help, especially if
coupled with proper assessment of data quality, since registries can
have limitations due to selection bias and missing data. Nowadays, it
is clear that there is a need for a continuous evaluation of the clinical
and economic impact of current approaches to manage HF, focusing
on all the treatment options that are available in appropriately se-
lected patients, including device therapy with CRT. The involvement
of different specialists, as well as of patients and caregivers, is needed,
in line with the concepts of disease management and of health tech-
nology assessment.1,5
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